Abstract
Among 582 participants in Western Kenya who were retrospectively tested from January through March 2020, 19 (3.3%) had detectable SARS-CoV-2 antibodies. The prevalence of detectable SARS-CoV-2 antibodies was similar between participants with and without HIV (3.1% vs. 4%, P = 0.68). One participant reported a cough in the preceding week but others denied symptoms. These may represent cross-reactivity or asymptomatic infections that predated the first reported COVID-19 cases in Kenya.
All Keywords
【초록키워드】 HIV, cough, Symptoms, cross-reactivity, asymptomatic infections, Prevalence, SARS-CoV-2 antibodies, SARS-CoV-2 antibody, Kenya, asymptomatic infection, COVID-19 case, participant, tested, reported, detectable, 【제목키워드】 HIV, antibody, Prevalence, Coronavirus-2, acute respiratory syndrome,
【초록키워드】 HIV, cough, Symptoms, cross-reactivity, asymptomatic infections, Prevalence, SARS-CoV-2 antibodies, SARS-CoV-2 antibody, Kenya, asymptomatic infection, COVID-19 case, participant, tested, reported, detectable, 【제목키워드】 HIV, antibody, Prevalence, Coronavirus-2, acute respiratory syndrome,
{{{ 추상적인 }}}
2020년 1월부터 3월까지 후향적으로 검사를 받은 서부 케냐의 참가자 582명 중 19명(3.3%)이 SARS-CoV-2 항체를 검출했습니다. 검출 가능한 SARS-CoV-2 항체의 유병률은 HIV 유무에 관계없이 참가자 간에 유사했습니다(3.1% 대 4%, P = 0.68). 한 참가자는 이전 주에 기침을 보고했지만 다른 참가자는 증상을 거부했습니다. 이는 케냐에서 처음 보고된 COVID-19 사례보다 앞선 교차 반응성 또는 무증상 감염을 나타낼 수 있습니다.